Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Soluble Urokinase Plasminogen Activation Receptor (SUPAR) is a validated biomarker with applications in the study of inflammation and infection.
Elevated levels of SUPAR have recently been linked to a higher mortality in patients suffering from undifferentiated sepsis, pneumonia, and more recently, COVID-19 infection.
Large randomized controlled trials have been conducted on patients admitted to the emergency department (ER), regardless of the reason for admittance.
These studies have stratified risk based on three cutoffs at initial measurement:
To the best of our knowledge, there is no available data on the added value of SUPAR for predicting mortality in abdominal sepsis and abdominal pain.
Abdominal pain is responsible for 10 to 30 % of ER admissions. Consequently, abdominal pain is then responsible for roughly 10 % of admissions into medical and surgical wards. Mortality varies depending on patient factors. Mortality is usually stratified on age. In patients under 50 years of age, it is near 8%, but it reaches 19 % in patients over 50.
Diagnostic accuracy also decreases drastically with age, reaching approximately 30 % patients over 75.
Taking this into account, integrating a measure of SUPAR levels into the current standard of care could stratify the risk of complications in patients admitted to the ER with abdominal pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Soluble Urokinase Plasminogen Activation Receptor measurement |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Soluble Urokinase Plasminogen Activation Receptor measurement | Diagnostic Test | In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of medical and surgical complications within 7 days | 7 -day complications as a composite outcome of either:
| 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of medical and surgical complications within 30 days | 30 -day complications as a composite outcome of either:
| 30 days |
Not provided
Inclusion Criteria:
Patients :
Exclusion Criteria:
Patients :
Not provided
Not provided
Not provided
Patients admitted to the emergency department for abdominal pain
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU of Poitiers | Poitiers | 86021 | France |
Not provided
Not provided
Not provided
Not provided
| Optimal cutoff |
Determining optimal cutoffs for Soluble Urokinase Plasminogen Activation Receptor through Area Under Curve using Receiver Operating Characteristic method for patients presenting complications of abdominal pain in the first seven days. |
| 7 days |
| Comparison with routine biomarkers | Comparison of diagnostic performance with other routine biomarkers: Procalcitonine C-Reactive Protein Lactate | 30 days |
| ID | Term |
|---|---|
| D015746 | Abdominal Pain |
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012817 | Signs and Symptoms, Digestive |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided